Control of Regulatory T Cell Function by Toll-Like Receptor 7

Toll 样受体 7 对调节性 T 细胞功能的控制

基本信息

  • 批准号:
    10438923
  • 负责人:
  • 金额:
    $ 56.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Regulatory T cells (Tregs) are critical for the maintenance of immunological tolerance but more recently their importance in regulating other aspects of tissue homeostasis has been an area of intense interest. Most relevant to this application are populations of tissue-resident Tregs that accumulate upon injury and facilitate tissue repair by producing factors such as the EGF family member amphiregulin (Areg). These repair functions are distinct from the suppressive function classically attributed to Tregs, but the signals that instruct Tregs to adopt these distinct functional modalities have not been well defined. The IL-1 family cytokines IL-18 and IL-33 are involved at some level, at least in certain tissues, but it remains unclear whether these cytokines act as the key initial determinants of Treg function. This proposal will test the hypothesis that Toll-like receptor 7 (TLR7) signaling in Tregs is a key determinant of Treg tissue repair function. We propose that TLR7 enables Tregs to sense pathogen-derived nucleic acids as well as self RNA released from damaged host tissues. Our hypothesis is based on our analysis of a panel of TLR reporter mice, which revealed that only TLR7 is expressed on Tregs, as well as strong preliminary data demonstrating that TLR7 can induce expression of the signature tissue repair gene, Areg, in both murine and human Tregs. Using newly generated mice with Treg-specific deletion of TLR7, we will examine the importance of TLR7 signaling in Tregs during lung damage (Aim 1). Single-cell RNA sequencing will identify which subsets of lung Tregs are controlled by TLR7 and will define TLR7-dependent genes in Tregs. We will also investigate the importance of IL18R and IL33R signaling in Tregs, using mice with Treg-specific deletion of these receptors, and will determine the extent to which TLR7, IL18R, and IL33R regulate distinct aspects of Treg expansion and/or differentiation in response to diverse lung damaging agents (Aim 2). Finally, we will build on our recent work that identified a mechanism by which the TLR chaperone Unc93b1 specifically dampens TLR7 signaling. Using Tregs from mice with mutant Unc93b1 that have enhanced TLR7 signaling, we will test whether adoptive therapy of Tregs with enhanced TLR7 responses to viral and self RNA can mediate more effective repair of lung damage (Aim 3). Altogether, these studies will define the signals that control Treg tissue repair functions and test the therapeutic potential of amplifying these signals in the context of lung damage, a key first step toward therapeutic manipulation of Treg function for clinical benefit.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory M Barton其他文献

Toll signaling: RIPping off the TNF pathway
收费信号:利用肿瘤坏死因子通路
  • DOI:
    10.1038/ni0504-472
  • 发表时间:
    2004-05-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Gregory M Barton;Ruslan Medzhitov
  • 通讯作者:
    Ruslan Medzhitov
The path ahead for understanding Toll-like receptor-driven systemic autoimmunity
理解 Toll 样受体驱动的全身性自身免疫的未来之路
  • DOI:
    10.1016/j.coi.2024.102482
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    5.800
  • 作者:
    Jessica A Hamerman;Gregory M Barton
  • 通讯作者:
    Gregory M Barton
Unfolding new roles for XBP1 in immunity
揭示 XBP1 在免疫中的新作用
  • DOI:
    10.1038/ni0510-365
  • 发表时间:
    2010-05-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Alex Engel;Gregory M Barton
  • 通讯作者:
    Gregory M Barton

Gregory M Barton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory M Barton', 18)}}的其他基金

The Signal Transduction in the Immune System Conference
免疫系统会议中的信号转导
  • 批准号:
    10683527
  • 财政年份:
    2023
  • 资助金额:
    $ 56.43万
  • 项目类别:
Control of Regulatory T Cell Function by Toll-Like Receptor 7
Toll 样受体 7 对调节性 T 细胞功能的控制
  • 批准号:
    10650735
  • 财政年份:
    2021
  • 资助金额:
    $ 56.43万
  • 项目类别:
Control of Regulatory T Cell Function by Toll-Like Receptor 7
Toll 样受体 7 对调节性 T 细胞功能的控制
  • 批准号:
    10304769
  • 财政年份:
    2021
  • 资助金额:
    $ 56.43万
  • 项目类别:
The influence of maternal antibodies on neonatal intestinal immunity
母源抗体对新生儿肠道免疫的影响
  • 批准号:
    9677877
  • 财政年份:
    2018
  • 资助金额:
    $ 56.43万
  • 项目类别:
The influence of maternal antibodies on neonatal intestinal immunity
母源抗体对新生儿肠道免疫的影响
  • 批准号:
    9790941
  • 财政年份:
    2018
  • 资助金额:
    $ 56.43万
  • 项目类别:
Molecular Determinants of TLR Trafficking
TLR 贩运的分子决定因素
  • 批准号:
    8697654
  • 财政年份:
    2014
  • 资助金额:
    $ 56.43万
  • 项目类别:
Molecular Determinants of TLR Trafficking
TLR 贩运的分子决定因素
  • 批准号:
    9120303
  • 财政年份:
    2014
  • 资助金额:
    $ 56.43万
  • 项目类别:
Innate immunity and Salmonella pathogenesis
先天免疫和沙门氏菌发病机制
  • 批准号:
    8478572
  • 财政年份:
    2013
  • 资助金额:
    $ 56.43万
  • 项目类别:
Innate immunity and Salmonella pathogenesis
先天免疫和沙门氏菌发病机制
  • 批准号:
    8786055
  • 财政年份:
    2013
  • 资助金额:
    $ 56.43万
  • 项目类别:
Innate immunity and Salmonella pathogenesis
先天免疫和沙门氏菌发病机制
  • 批准号:
    8605519
  • 财政年份:
    2013
  • 资助金额:
    $ 56.43万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 56.43万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 56.43万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 56.43万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 56.43万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 56.43万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 56.43万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 56.43万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 56.43万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 56.43万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 56.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了